Currently, Ionis Pharmaceuticals Inc [IONS] is trading at $51.45, down -0.79%. An important factor to consider is whether the stock is rising or falling in short-term value. The IONS shares have gain 7.59% over the last week, with a monthly amount glided 7.86%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Ionis Pharmaceuticals Inc [NASDAQ: IONS] stock has seen the most recent analyst activity on July 24, 2024, when Leerink Partners upgraded its rating to a Outperform and also boosted its price target to $62 from $53. On June 14, 2024, upgrade upgraded it’s rating to Mkt Perform but maintained its price target of $44 on the stock. Wolfe Research upgraded its rating to a Outperform but stick to its price target of $58 on April 10, 2024. BofA Securities upgraded its rating to a Buy and raised its price target to $62 on January 02, 2024. BofA Securities upgraded its rating to Neutral for this stock on October 23, 2023, and upped its price target to $52. In a note dated September 29, 2023, Raymond James initiated an Strong Buy rating and provided a target price of $63 on this stock.
This stock has fluctuated between a low of $35.95 and a high of $54.44 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $51.28 within the next 12 months. Ionis Pharmaceuticals Inc [NASDAQ: IONS] shares were valued at $51.45 at the most recent close of the market. An investor can expect a potential drop of -0.33% based on the average IONS price forecast.
Analyzing the IONS fundamentals
Trailing Twelve Months sales for Ionis Pharmaceuticals Inc [NASDAQ:IONS] were 777.12M which represents -8.45% decline. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -0.5%, Pretax Profit Margin comes in at -0.47%, and Net Profit Margin reading is -0.49%. To continue investigating profitability, this company’s Return on Assets is posted at -0.14, Equity is -1.08 and Total Capital is -0.16. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of6.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 50.88 points at the first support level, and at 50.31 for the second support level. However, for the 1st resistance point, the stock is sitting at 52.18, and for the 2nd resistance point, it is at 52.91.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Ionis Pharmaceuticals Inc [NASDAQ:IONS] is 7.37. On the other hand, the Quick Ratio is 7.28, and the Cash Ratio is 1.06. Considering the valuation of this stock, the price to sales ratio is 9.66, the price to book ratio is 25.31.
Transactions by insiders
Recent insider trading involved KLEIN JOSEPH III, Director, that happened on Jul 16 ’24 when 12000.0 shares were sold. Director, Diaz Allene M. completed a deal on Jul 16 ’24 to sell 1637.0 shares. Meanwhile, Director BERTHELSEN SPENCER R sold 16000.0 shares on Jun 17 ’24.
